We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

OssDsign AB (OSSD) NPV

Sell:9.16 SEK Buy:9.27 SEK Change: 0.1 SEK (1.08%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:9.16 SEK
Buy:9.27 SEK
Change: 0.1 SEK (1.08%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:9.16 SEK
Buy:9.27 SEK
Change: 0.1 SEK (1.08%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

OssDsign AB, formerly known as Oss-Q AB is a Sweden-based orthopedic medical device company. It aims at developing implantable products that respond to clinical challenges, with focus on bone healing. Its primary focus is skull surgery. The Company uses design solutions, material compositions and manufacturing processes mainly based on proprietary bioceramic technologies. The bioceramics it uses integrate with tissues and support bone ingrowth. OssDsign AB's main product is Craniomosaic, an implant for the repair of skull defects (cranioplasty). Along with it, the Company develops bioceramic implants for facial bone augmentation. The Company's customers include neurosurgeons, craniofacial and maxillofacial surgeons.

Contact details

Address:
Rapsgatan 23 A
UPPSALA
754 50
Sweden
Telephone:
+46 (18) 553993
Website:
https://www.ossdsign.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OSSD
ISIN:
SE0012570448
Market cap:
900.42 million SEK
Shares in issue:
97.66 million
Sector:
Health Care Supplies
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Anders Lundqvist
    Chief Executive Officer
  • Anders Svensson
    Chief Financial Officer
  • Kajsa Bjorklund
    Director of Technical Operations
  • Rick Thomas
    Vice President Commercial Operations
  • Henrik Hjort
    Director of Marketing & Business Development
  • Ulrik Birgersson
    Director Clinical Engineering
  • Malin Kylberg
    Quality Assurance Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.